New accelerate pheno® landmark study validates important clinical benefits to be presented at eccmid 2021

Tucson, ariz., june 30, 2021 /prnewswire/ -- accelerate diagnostics, inc. (nasdaq:axdx) today announced that it will have 3 data presentations from its improving outcomes and antibiotic stewardship (ioas) study at the european congress of clinical microbiology & infectious diseases (eccmid) to be held july 9–12, 2021.

AXDX Ratings Summary

AXDX Quant Ranking